No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d2hd1A_, 1.0000, 0.00, 1.000, 326, 326, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH IBMX
2, d1tbmA_, 0.9999, 0.00, 1.000, 326, 326,  
3, d2yy2A_, 0.9991, 0.00, 1.000, 326, 326, CRYSTAL STRUCTURE OF THE HUMAN PHOSPHODIESTERASE 9A CATALYTIC DOMAIN COMPLEXED WITH IBMX
4, d4gh6A_, 0.9975, 0.19, 1.000, 326, 326, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 28
5, d3n3zA_, 0.9965, 0.34, 1.000, 326, 326, CRYSTAL STRUCTURE OF PDE9A (E406A) MUTANT IN COMPLEX WITH IBMX
6, d3qi4A_, 0.9954, 0.39, 0.997, 326, 326, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH IBMX
7, d3qi3A_, 0.9939, 0.26, 0.997, 325, 325, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH INHIBITOR BAY73-6691
8, d3dyqA2, 0.9932, 0.37, 0.997, 325, 325, HUMAN PHOSPHODIESTRASE 9 (INHIBITED BY OMITTING DIVALENT CATION) IN COMPLEX WITH CGMP
9, d3dy8A2, 0.9931, 0.16, 1.000, 324, 324, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH PRODUCT 5 -GMP (E+P COMPLEX)
10, d3dylA2, 0.9930, 0.17, 1.000, 324, 324, HUMAN PHOSPHDIESTERASE 9 SUBSTRATE COMPLEX (ES COMPLEX)
11, d3dynA2, 0.9927, 0.19, 1.000, 324, 324, HUMAN PHOSPHODIESTRASE 9 IN COMPLEX WITH CGMP (ZN INHIBITED)
12, d3dysA_, 0.9925, 0.22, 1.000, 324, 324, HUMAN PHOSPHODIESTRASE-5 GMP COMPLEX (EP) PRODUCED BY SOAKING WITH 20MM CGMP+20 MM MNCL2+20 MM MGCL2 FOR 2 HOURS AND FLASH-COOLED TO LIQUID NITROGEN TEMPERATURE WHEN SUBSTRATE WAS STILL ABUDANT.
13, d4g2jA1, 0.9924, 0.25, 1.000, 324, 324, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
14, d4g2lA1, 0.9922, 0.25, 1.000, 324, 324, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
15, d3jswA1, 0.9920, 0.27, 1.000, 324, 324, HUMAN PDE9 IN COMPLEX WITH SELECTIVE INHIBITOR
16, d3jsiA1, 0.9915, 0.29, 1.000, 324, 324, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITOR
17, d2hd1B_, 0.9915, 0.32, 1.000, 324, 324, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH IBMX
18, d1tbmB_, 0.9915, 0.79, 1.000, 326, 326,  
19, d4e90A1, 0.9910, 0.79, 1.000, 326, 326, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITORS
20, d4gh6B_, 0.9908, 0.36, 1.000, 324, 324, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 28
21, d4y86B_, 0.9905, 0.81, 1.000, 326, 326, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH RACEMIC INHIBITOR C33
22, d4y87B_, 0.9904, 0.84, 1.000, 326, 326, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (R)-C33 (6- {[(1R)-1-(4-CHLOROPHENYL)ETHYL]AMINO}-1-CYCLOPENTYL-15-DIHYDRO-4H- PYRAZOLO[34-D]PYRIMIDIN-4-ONE)
23, d3qi4B_, 0.9903, 0.84, 1.000, 326, 326, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH IBMX
24, d4y8cB_, 0.9898, 0.59, 0.997, 325, 325, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (S)-C33
25, d3n3zB_, 0.9894, 0.89, 1.000, 326, 326, CRYSTAL STRUCTURE OF PDE9A (E406A) MUTANT IN COMPLEX WITH IBMX
26, d2yy2B_, 0.9883, 0.84, 0.997, 326, 326, CRYSTAL STRUCTURE OF THE HUMAN PHOSPHODIESTERASE 9A CATALYTIC DOMAIN COMPLEXED WITH IBMX
27, d3dylB2, 0.9880, 0.52, 1.000, 324, 324, HUMAN PHOSPHDIESTERASE 9 SUBSTRATE COMPLEX (ES COMPLEX)
28, d3dysB2, 0.9877, 0.56, 1.000, 324, 324, HUMAN PHOSPHODIESTRASE-5 GMP COMPLEX (EP) PRODUCED BY SOAKING WITH 20MM CGMP+20 MM MNCL2+20 MM MGCL2 FOR 2 HOURS AND FLASH-COOLED TO LIQUID NITROGEN TEMPERATURE WHEN SUBSTRATE WAS STILL ABUDANT.
29, d3dynB2, 0.9876, 0.58, 1.000, 324, 324, HUMAN PHOSPHODIESTRASE 9 IN COMPLEX WITH CGMP (ZN INHIBITED)
30, d3dyqB2, 0.9875, 0.58, 1.000, 324, 324, HUMAN PHOSPHODIESTRASE 9 (INHIBITED BY OMITTING DIVALENT CATION) IN COMPLEX WITH CGMP
31, d3dy8B2, 0.9875, 0.59, 1.000, 324, 324, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH PRODUCT 5 -GMP (E+P COMPLEX)
32, d4g2jB1, 0.9874, 0.58, 1.000, 324, 324, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
33, d4g2lB1, 0.9872, 0.58, 1.000, 324, 324, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
34, d3qi3B_, 0.9869, 0.59, 1.000, 324, 324, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH INHIBITOR BAY73-6691
35, d4e90B1, 0.9858, 0.73, 0.997, 325, 325, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITORS
36, d3jswB1, 0.9857, 0.66, 1.000, 324, 324, HUMAN PDE9 IN COMPLEX WITH SELECTIVE INHIBITOR
37, d3jsiB1, 0.9857, 0.66, 1.000, 324, 324, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITOR
38, d4qgeA_, 0.9853, 0.67, 1.000, 324, 324, PHOSPHODIESTERASE-9A IN COMPLEX WITH INHIBITOR WYQ-C36D
39, d4y86A_, 0.9852, 0.34, 1.000, 322, 322, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH RACEMIC INHIBITOR C33
40, d4y8cA_, 0.9842, 0.34, 1.000, 322, 322, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (S)-C33
41, d4y87A_, 0.9834, 0.40, 1.000, 322, 322, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (R)-C33 (6- {[(1R)-1-(4-CHLOROPHENYL)ETHYL]AMINO}-1-CYCLOPENTYL-15-DIHYDRO-4H- PYRAZOLO[34-D]PYRIMIDIN-4-ONE)
42, d3k3hA_, 0.9789, 0.45, 1.000, 322, 322, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (S)- BAY73-6691
43, d4qgeB_, 0.9756, 0.35, 1.000, 320, 320, PHOSPHODIESTERASE-9A IN COMPLEX WITH INHIBITOR WYQ-C36D
44, d3k3eA_, 0.9755, 0.55, 1.000, 320, 320, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (R)- BAY73-6691
45, d3k3hB_, 0.9723, 0.37, 1.000, 319, 319, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (S)- BAY73-6691
46, d3k3eB_, 0.9685, 0.70, 1.000, 320, 320, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (R)- BAY73-6691
47, d5u7dC_, 0.9286, 0.71, 1.000, 319, 319, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
48, d5tzcD_, 0.9286, 2.12, 0.261, 338, 322, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
49, d5u00D_, 0.9283, 2.21, 0.257, 336, 323, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
50, d5u7kC_, 0.9279, 2.19, 0.257, 336, 323, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
51, d5tzzD_, 0.9278, 2.19, 0.260, 339, 323, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
52, d5tzaD_, 0.9274, 2.10, 0.258, 332, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
53, d4jibD_, 0.9270, 2.14, 0.258, 333, 322, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
54, d4htxD_, 0.9270, 2.14, 0.261, 335, 322, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
55, d5tz3D_, 0.9264, 1.94, 0.262, 327, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
56, d5tzcC1, 0.9263, 1.93, 0.259, 327, 320, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
57, d4d08B_, 0.9263, 2.03, 0.259, 339, 321, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
58, d5tzwD_, 0.9262, 2.16, 0.261, 337, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
59, d5tzhD_, 0.9262, 1.94, 0.259, 327, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
60, d3ituD_, 0.9262, 1.93, 0.259, 327, 320, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
61, d5tzwB1, 0.9261, 1.95, 0.259, 327, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
62, d5tz3B1, 0.9261, 2.15, 0.261, 338, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
63, d5tzxD_, 0.9260, 2.15, 0.258, 338, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
64, d5tz3C_, 0.9259, 1.94, 0.259, 328, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
65, d5xkmA_, 0.9258, 2.02, 0.262, 334, 321, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
66, d5u7jD_, 0.9256, 2.12, 0.261, 340, 322, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
67, d5xkmB1, 0.9255, 1.99, 0.259, 327, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
68, d5tzhB1, 0.9255, 2.12, 0.258, 342, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
69, d4d09B_, 0.9255, 2.16, 0.258, 338, 322, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
70, d5xkmC1, 0.9254, 2.14, 0.261, 338, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
71, d5u00C1, 0.9254, 2.12, 0.258, 340, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
72, d5u00B1, 0.9253, 2.05, 0.262, 338, 321, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
73, d5tzcB1, 0.9252, 2.16, 0.261, 338, 322, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
74, d5tzaB1, 0.9252, 2.17, 0.258, 340, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
75, d4htzD_, 0.9252, 2.21, 0.261, 337, 322, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
76, d4d08D1, 0.9252, 1.90, 0.260, 326, 319, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
77, d4htxA_, 0.9251, 1.99, 0.262, 332, 320, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
78, d4d09D_, 0.9251, 2.06, 0.262, 338, 321, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
79, d5tzwC_, 0.9250, 2.02, 0.262, 326, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
80, d5u7jC_, 0.9249, 1.97, 0.259, 328, 320, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
81, d5u7iD_, 0.9249, 2.00, 0.259, 327, 320, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
82, d5tzxC_, 0.9249, 1.92, 0.263, 324, 319, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
83, d5tzhC_, 0.9249, 1.96, 0.259, 327, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
84, d3ituC_, 0.9249, 1.97, 0.259, 327, 320, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
85, d5xkmD_, 0.9248, 2.00, 0.259, 327, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
86, d5tzzC_, 0.9248, 2.19, 0.258, 337, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
87, d5tzxA1, 0.9248, 1.97, 0.259, 327, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
88, d5tzwA1, 0.9248, 2.04, 0.262, 339, 321, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
89, d4jibA1, 0.9248, 2.05, 0.262, 339, 321, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
90, d5u7kD_, 0.9247, 2.06, 0.259, 338, 321, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
91, d5u7iC_, 0.9247, 1.97, 0.259, 327, 320, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
92, d5tzzB1, 0.9247, 1.99, 0.259, 327, 320, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
93, d5tzaC_, 0.9247, 2.17, 0.261, 338, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
94, d5u7iA_, 0.9246, 1.99, 0.259, 328, 320, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
95, d5tzaA1, 0.9246, 2.06, 0.259, 338, 321, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
96, d5vp0A_, 0.9245, 2.07, 0.262, 338, 321, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
97, d5tzzA1, 0.9245, 2.15, 0.258, 334, 322, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
98, d3ituA_, 0.9245, 2.06, 0.262, 339, 321, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
99, d5tzhA1, 0.9244, 2.07, 0.259, 338, 321, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
100, d5tzcA1, 0.9244, 2.06, 0.259, 338, 321, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
101, d5tz3A1, 0.9244, 2.07, 0.262, 340, 321, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
102, d5tzxB_, 0.9243, 2.05, 0.262, 338, 321, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
103, d4htzA_, 0.9242, 2.23, 0.258, 337, 322, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
104, d5u7lC_, 0.9241, 2.07, 0.262, 338, 321, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
105, d5u7jA_, 0.9241, 2.16, 0.261, 338, 322, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
106, d4d08A_, 0.9241, 2.08, 0.262, 338, 321, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
107, d5u00A1, 0.9240, 2.08, 0.262, 339, 321, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
108, d4d09C_, 0.9240, 2.06, 0.262, 338, 321, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
109, d4d08C_, 0.9240, 2.10, 0.262, 329, 321, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
110, d4jibC_, 0.9239, 2.02, 0.262, 327, 320, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
111, d4htxB_, 0.9238, 2.01, 0.262, 327, 320, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
112, d5u7jB_, 0.9237, 2.23, 0.261, 336, 322, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
113, d5u7dA_, 0.9235, 2.25, 0.258, 336, 322, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
114, d5u7kA1, 0.9234, 2.06, 0.259, 338, 321, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
115, d5u7iB_, 0.9233, 2.22, 0.261, 338, 322, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
116, d4htxC_, 0.9232, 2.27, 0.258, 336, 322, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
117, d4jibB_, 0.9231, 1.98, 0.260, 325, 319, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
118, d4d09A_, 0.9230, 2.26, 0.258, 336, 322, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
119, d5u7kB1, 0.9228, 2.08, 0.262, 340, 321, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
120, d5u7lA_, 0.9225, 2.09, 0.262, 340, 321, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
121, d4htzB_, 0.9225, 2.09, 0.262, 339, 321, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
122, d5vp0B_, 0.9222, 2.21, 0.261, 337, 322, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
123, d4htzC_, 0.9222, 2.07, 0.262, 339, 321, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
124, p5vp1B_, 0.9176, 2.00, 0.260, 325, 319, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
125, d3ituB_, 0.9174, 1.88, 0.263, 331, 316, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
126, d4c1iA_, 0.9170, 2.28, 0.262, 333, 320, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
127, d3v9bA_, 0.9165, 1.85, 0.263, 325, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
128, d5wqaA_, 0.9164, 1.78, 0.291, 331, 316, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN COMPLEXED WITH SELAGINPULVILINS K
129, d1ptwA_, 0.9162, 1.77, 0.291, 334, 316, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
130, d1q9mC_, 0.9158, 1.79, 0.291, 334, 316, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
131, d1q9mA_, 0.9156, 1.78, 0.291, 329, 316, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
132, d1oymA_, 0.9156, 1.79, 0.291, 334, 316,  
133, d1oynA_, 0.9152, 1.79, 0.291, 334, 316, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
134, p6b98A_, 0.9151, 1.79, 0.291, 334, 316, PDE2 IN COMPLEX WITH COMPOUND 1
135, d3g58A_, 0.9151, 2.10, 0.259, 344, 317, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
136, d3d3pA_, 0.9151, 1.79, 0.291, 335, 316, CRYSTAL STRUCTURE OF PDE4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIDINE INHIBITOR
137, d5wqaB_, 0.9149, 1.87, 0.288, 336, 316, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN COMPLEXED WITH SELAGINPULVILINS K
138, p6b97B_, 0.9148, 1.80, 0.291, 334, 316, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPLEX 9
139, d3frgA_, 0.9148, 2.01, 0.263, 348, 316, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A QUINOLINE INHIBITOR
140, d3o57A_, 0.9147, 2.01, 0.263, 348, 316, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A 5- HETEROCYCLE PYRAZOLOPYRIDINE INHIBITOR
141, d1mkdJ_, 0.9147, 1.88, 0.288, 335, 316, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
142, d1mkdE_, 0.9147, 1.88, 0.288, 336, 316, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
143, d1mkdA_, 0.9147, 1.76, 0.298, 328, 315, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
144, d1ro9A_, 0.9146, 1.76, 0.298, 328, 315, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH 8-BR-AMP
145, d1mkdK_, 0.9146, 1.76, 0.298, 328, 315, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
146, d1mkdH_, 0.9146, 1.94, 0.286, 338, 318, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
147, d1mkdG_, 0.9146, 1.77, 0.298, 328, 315, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
148, d1mkdF_, 0.9146, 1.77, 0.298, 328, 315, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
149, d1mkdD_, 0.9146, 1.77, 0.298, 328, 315, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
150, d1mkdC_, 0.9146, 1.77, 0.298, 328, 315, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
151, d1mkdB_, 0.9146, 1.77, 0.298, 328, 315, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
152, d1mkdL_, 0.9145, 1.77, 0.298, 328, 315, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
153, d1mkdI_, 0.9145, 1.77, 0.298, 328, 315, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
154, d3gwtA_, 0.9143, 1.77, 0.298, 328, 315, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A QUINOLINE INHIBITOR
155, d3o56A_, 0.9142, 1.77, 0.298, 328, 315, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A 5- HETEROCYCLE PYRAZOLOPYRIDINE INHIBITOR
156, d3g4iA_, 0.9142, 1.88, 0.288, 336, 316, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
157, p5tkbA_, 0.9141, 1.89, 0.288, 335, 316, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
158, p5lboA_, 0.9140, 1.81, 0.291, 331, 316, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
159, d1rorA_, 0.9138, 1.82, 0.291, 326, 316, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH AMP
160, d2fm0A_, 0.9137, 1.78, 0.292, 330, 315, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
161, d1zknA_, 0.9137, 1.95, 0.286, 338, 318, STRUCTURE OF PDE4D2-IBMX
162, d1rkoA_, 0.9137, 1.82, 0.291, 334, 316,  
163, d3g4lA_, 0.9135, 1.82, 0.291, 334, 316, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
164, d3sl4A_, 0.9133, 1.82, 0.291, 334, 316, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
165, d2pw3A_, 0.9133, 1.77, 0.292, 327, 315, STRUCTURE OF THE PDE4D-CAMP COMPLEX
166, d2fm5A_, 0.9128, 1.79, 0.292, 329, 315, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
167, d1t9sA_, 0.9128, 1.73, 0.296, 327, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH GMP
168, d1xorB_, 0.9127, 1.83, 0.291, 334, 316, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ZARDAVERINE
169, d1zknC_, 0.9126, 1.69, 0.296, 326, 311, STRUCTURE OF PDE4D2-IBMX
170, d1rkoC_, 0.9126, 1.75, 0.299, 327, 314,  
171, d3g4kA_, 0.9125, 1.86, 0.291, 330, 316, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
172, d5k1iA_, 0.9124, 1.86, 0.291, 330, 316, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
173, d3v9bB_, 0.9123, 1.79, 0.292, 330, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
174, d2qynA_, 0.9122, 1.62, 0.298, 322, 312, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR NPV
175, d1t9sB_, 0.9122, 1.73, 0.299, 327, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH GMP
176, d4w1oB_, 0.9121, 1.68, 0.300, 326, 313, PDE4D COMPLEXED WITH INHIBITOR
177, d1f0jA_, 0.9119, 1.67, 0.296, 326, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B
178, d3sl5A_, 0.9118, 1.80, 0.292, 325, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
179, d3jwqC1, 0.9117, 2.01, 0.286, 351, 318, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
180, d1ptwD_, 0.9117, 1.77, 0.293, 328, 314, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
181, d3g58B_, 0.9115, 1.69, 0.283, 325, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
182, d3g4lD_, 0.9115, 1.75, 0.293, 334, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
183, d3g4iD_, 0.9114, 1.75, 0.299, 327, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
184, p3g4gC_, 0.9114, 1.75, 0.293, 334, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
185, d1q9mB_, 0.9113, 1.76, 0.293, 334, 314, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
186, d3g58C_, 0.9112, 1.67, 0.291, 339, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
187, d3v9bD_, 0.9111, 1.77, 0.296, 327, 314, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
188, d3g4iC_, 0.9111, 1.78, 0.299, 327, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
189, d1oynD_, 0.9111, 1.72, 0.297, 326, 313, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
190, p3g45A_, 0.9110, 1.78, 0.299, 327, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B WITH REGULATORY DOMAIN AND D155988
191, d1ptwB_, 0.9110, 1.76, 0.293, 334, 314, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
192, d1oynC_, 0.9110, 2.01, 0.285, 371, 316, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
193, d1oymB_, 0.9110, 2.01, 0.285, 371, 316,  
194, p5laqA_, 0.9109, 1.78, 0.299, 327, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN WITH INHIBITOR NPD-001
195, d3jwqA_, 0.9109, 1.77, 0.299, 327, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
196, d3g4kC_, 0.9109, 1.77, 0.296, 327, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
197, d1zknD_, 0.9109, 1.97, 0.285, 337, 316, STRUCTURE OF PDE4D2-IBMX
198, d1y2cA_, 0.9109, 1.70, 0.283, 324, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
199, d1tb7B_, 0.9109, 1.77, 0.299, 327, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH AMP
200, d1rkoD_, 0.9109, 1.76, 0.293, 334, 314,  
201, d1q9mD_, 0.9108, 1.72, 0.300, 326, 313, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
202, p5tkbC_, 0.9107, 1.73, 0.300, 326, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
203, d4myqA_, 0.9107, 1.76, 0.293, 334, 314, SELECTIVE INHIBITION OF THE CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B WITH A-33
204, p5vp1A_, 0.9106, 1.76, 0.293, 334, 314, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
205, d2qynB_, 0.9106, 1.78, 0.299, 323, 314, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR NPV
206, d3g4kD_, 0.9105, 1.79, 0.287, 345, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
207, d1y2kA_, 0.9105, 1.85, 0.265, 324, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
208, d1ptwC_, 0.9105, 1.68, 0.298, 325, 312, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
209, d3g4iB_, 0.9104, 1.78, 0.293, 333, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
210, d3g58D_, 0.9103, 1.73, 0.300, 326, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
211, d1y2cB_, 0.9103, 1.78, 0.296, 327, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
212, d1tbbB_, 0.9103, 1.71, 0.297, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROLIPRAM
213, p5wh6A_, 0.9102, 1.78, 0.293, 345, 314, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR (S_ZL-N-91) 
214, d3g4kB_, 0.9102, 1.72, 0.300, 326, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
215, d1oynB_, 0.9102, 1.74, 0.297, 326, 313, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
216, d1y2dA_, 0.9101, 1.72, 0.300, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- METHOXY-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
217, d1y2bA_, 0.9100, 1.71, 0.297, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
218, d2fm0D_, 0.9099, 1.78, 0.299, 327, 314, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
219, d1xoqA_, 0.9099, 1.74, 0.300, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROFLUMILAST
220, d5k1iD_, 0.9098, 1.74, 0.300, 326, 313, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
221, p4ogbA_, 0.9098, 1.79, 0.293, 334, 314, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
222, d1tb7A_, 0.9098, 1.74, 0.300, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH AMP
223, d5k1iH_, 0.9097, 1.74, 0.300, 326, 313, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
224, p3g45B_, 0.9097, 1.79, 0.293, 328, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B WITH REGULATORY DOMAIN AND D155988
225, d2pw3B_, 0.9097, 1.68, 0.298, 321, 312, STRUCTURE OF THE PDE4D-CAMP COMPLEX
226, d1y2eA_, 0.9097, 1.73, 0.300, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- AMINO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
227, d1ro6A_, 0.9097, 1.80, 0.287, 370, 314, CRYSTAL STRUCTURE OF PDE4B2B COMPLEXED WITH ROLIPRAM (R & S)
228, d5ohjA_, 0.9096, 1.67, 0.295, 325, 312, HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRROLIDINYL INHIBITOR.
229, d3sl6A_, 0.9096, 1.74, 0.300, 326, 313, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
230, d2fm0C_, 0.9096, 2.12, 0.286, 344, 318, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
231, d1y2bB_, 0.9096, 1.93, 0.286, 336, 315, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
232, d1xoqB_, 0.9096, 1.80, 0.293, 327, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROFLUMILAST
233, d3sl8A_, 0.9095, 1.79, 0.299, 327, 314, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
234, d1y2kB_, 0.9095, 1.74, 0.300, 322, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
235, d1y2dB_, 0.9095, 1.74, 0.300, 322, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- METHOXY-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
236, d2fm5C_, 0.9093, 1.80, 0.293, 327, 314, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
237, d1xomA_, 0.9092, 1.74, 0.300, 322, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH CILOMILAST
238, d3g4lB_, 0.9091, 1.74, 0.300, 326, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
239, d2fm5D_, 0.9091, 1.80, 0.299, 327, 314, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
240, d1xonA_, 0.9091, 1.75, 0.300, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH PICLAMILAST
241, p3g4gA_, 0.9090, 1.74, 0.297, 326, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
242, p5wh5A_, 0.9089, 1.80, 0.293, 334, 314, CRYSTAL STRUCTURE OF THE PDE4D2 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR (R)-ZL-N-91 
243, d1xonB_, 0.9088, 1.75, 0.300, 322, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH PICLAMILAST
244, d5k1iF_, 0.9085, 1.67, 0.298, 338, 312, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
245, d5k1iC_, 0.9084, 1.74, 0.300, 326, 313, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
246, d3g4lC_, 0.9084, 1.76, 0.300, 326, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
247, d2fm5B_, 0.9084, 1.75, 0.300, 326, 313, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
248, d1ro6B_, 0.9083, 1.70, 0.298, 321, 312, CRYSTAL STRUCTURE OF PDE4B2B COMPLEXED WITH ROLIPRAM (R & S)
249, p6f8wB_, 0.9082, 1.77, 0.300, 326, 313, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18A 
250, d5k1iB_, 0.9082, 1.81, 0.299, 327, 314, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
251, d2fm0B_, 0.9082, 2.07, 0.284, 344, 317, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
252, d3ly2F_, 0.9081, 1.78, 0.294, 331, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
253, d1xp0A_, 0.9081, 1.76, 0.300, 326, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH VARDENAFIL
254, d1tbfA_, 0.9081, 1.81, 0.299, 327, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH SILDENAFIL
255, d5k1iG_, 0.9080, 1.89, 0.286, 329, 315, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
256, d4nw7A1, 0.9080, 1.76, 0.296, 326, 311, PDE4 CATALYTIC DOMAIN
257, d1zknB_, 0.9079, 1.74, 0.293, 326, 311, STRUCTURE OF PDE4D2-IBMX
258, d1rkoB_, 0.9079, 1.71, 0.298, 322, 312,  
259, p5tkbD_, 0.9078, 1.83, 0.287, 342, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
260, p6fdcA_, 0.9077, 1.81, 0.299, 327, 314, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 32A 
261, d3sl5D_, 0.9077, 1.81, 0.299, 327, 314, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
262, d1z1lA1, 0.9076, 1.71, 0.298, 325, 312, THE CRYSTAL STRUCTURE OF THE PHOSPHODIESTERASE 2A CATALYTIC DOMAIN
263, p5wh6B_, 0.9075, 1.74, 0.298, 329, 312, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR (S_ZL-N-91) 
264, d3iadD_, 0.9075, 1.64, 0.299, 324, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
265, p5tkbB_, 0.9074, 1.91, 0.268, 336, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
266, d3sl6B_, 0.9074, 1.74, 0.298, 325, 312, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
267, d3sl4B_, 0.9073, 1.71, 0.298, 339, 312, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
268, d1xozA_, 0.9072, 1.79, 0.294, 323, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH TADALAFIL
269, d3k4sA1, 0.9071, 1.70, 0.298, 325, 312, THE STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE4D WITH 4- (3-BUTOXY-4-METHOXYPHENYL)METHYL-2-IMIDAZOLIDONE
270, d3iadA_, 0.9071, 1.71, 0.298, 325, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
271, d1tb5A_, 0.9071, 1.77, 0.296, 326, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH AMP
272, p5wh5B_, 0.9070, 1.88, 0.299, 327, 314, CRYSTAL STRUCTURE OF THE PDE4D2 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR (R)-ZL-N-91 
273, d5k1iE_, 0.9069, 1.79, 0.294, 340, 313, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
274, d3jwrB1, 0.9069, 1.59, 0.294, 323, 310, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH 3-ISOBUTYL-1-METHYLXANTHINE (IBMX) AND PDE6 GAMMA-SUBUNIT INHIBITORY PEPTIDE 70-87.
275, p3jwrA_, 0.9069, 1.74, 0.298, 325, 312, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH 3-ISOBUTYL-1-METHYLXANTHINE (IBMX) AND PDE6 GAMMA-SUBUNIT INHIBITORY PEPTIDE 70-87.
276, p3jabO_, 0.9069, 1.73, 0.298, 321, 312, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
277, p3jabC_, 0.9069, 1.77, 0.283, 325, 311, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
278, d3iadB_, 0.9069, 1.77, 0.283, 323, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
279, d3hdzA_, 0.9069, 1.77, 0.283, 328, 311, IDENTIFICATION SYNTHESIS AND SAR OF AMINO SUBSTITUTED PYRIDO[3 2B]PRYAZIONES AS POTENT AND SELECTIVE PDE5 INHIBITORS
280, d1xorA_, 0.9068, 1.77, 0.283, 328, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ZARDAVERINE
281, p6f8vA_, 0.9067, 1.77, 0.283, 328, 311, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18B 
282, p5lboD_, 0.9066, 1.71, 0.298, 338, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
283, d3v9bC_, 0.9066, 1.77, 0.296, 323, 311, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
284, d3sl5B_, 0.9066, 1.68, 0.299, 321, 311, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
285, d5jo3B_, 0.9065, 1.77, 0.298, 327, 312, PDE5A FOR NAV1.7
286, p6f8tA_, 0.9064, 1.67, 0.299, 324, 311, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 4A 
287, p5lboB_, 0.9064, 1.74, 0.295, 325, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
288, d2chmA1, 0.9064, 1.72, 0.298, 325, 312, CRYSTAL STRUCTURE OF N2 SUBSTITUTED PYRAZOLO PYRIMIDINONES- A FLIPPED BINDING MODE IN PDE5
289, d1xmuA_, 0.9064, 1.78, 0.296, 323, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH ROFLUMILAST
290, p6f6uA_, 0.9063, 1.74, 0.295, 328, 312, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 7B 
291, d3sl8D_, 0.9063, 1.66, 0.296, 324, 311, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
292, d1tbbA_, 0.9063, 1.77, 0.296, 323, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROLIPRAM
293, d4wcuB_, 0.9062, 1.85, 0.291, 329, 313, PDE4 COMPLEXED WITH INHIBITOR
294, d3sl3A_, 0.9062, 1.74, 0.295, 328, 312, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
295, d3ecmA_, 0.9062, 1.67, 0.296, 324, 311, CRYSTAL STRUCTURE OF THE UNLIGANDED PDE8A CATALYTIC DOMAIN
296, d3hmvB_, 0.9061, 1.69, 0.299, 321, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A TETRAHYDROBENZOTHIOPHENE INHIBITOR
297, d1tb5B_, 0.9061, 1.78, 0.294, 333, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH AMP
298, p4w1oC_, 0.9059, 1.81, 0.294, 327, 313, PDE4D COMPLEXED WITH INHIBITOR
299, p4ogbD_, 0.9058, 1.77, 0.318, 338, 311, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
300, d3sl4C_, 0.9058, 1.77, 0.318, 338, 311, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
301, d1y2eB_, 0.9058, 1.95, 0.287, 351, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- AMINO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
302, d3sl5C_, 0.9057, 1.60, 0.294, 323, 310, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
303, d3sl4D_, 0.9056, 1.75, 0.298, 321, 312, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
304, d1rorB_, 0.9055, 1.69, 0.299, 324, 311, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH AMP
305, d3ly2B1, 0.9054, 1.75, 0.301, 325, 312, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
306, d3ly2D_, 0.9053, 1.69, 0.299, 320, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
307, d3hmvA_, 0.9053, 1.76, 0.301, 325, 312, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A TETRAHYDROBENZOTHIOPHENE INHIBITOR
308, d3ecnB_, 0.9053, 1.69, 0.299, 324, 311, CRYSTAL STRUCTURE OF PDE8A CATALYTIC DOMAIN IN COMPLEX WITH IBMX
309, d1xomB_, 0.9052, 2.02, 0.288, 337, 316, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH CILOMILAST
310, d3tggA_, 0.9051, 1.89, 0.287, 334, 314, A NOVEL SERIES OF POTENT AND SELECTIVE PDE5 INHIBITOR2
311, d3sl6D_, 0.9051, 1.89, 0.287, 328, 314, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
312, d3hc8A_, 0.9051, 1.83, 0.288, 351, 313, INVESTIGATION OF AMINOPYRIDIOPYRAZINONES AS PDE5 INHIBITORS: EVALUATION OF MODIFICATIONS TO THE CENTRAL RING SYSTEM.
313, p3g4gD_, 0.9051, 1.79, 0.318, 338, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
314, d1xotB_, 0.9051, 1.71, 0.299, 321, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH VARDENAFIL
315, d3sl6C_, 0.9050, 1.83, 0.293, 324, 311, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
316, d3sl3D_, 0.9050, 1.70, 0.299, 324, 311, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
317, d3iakA1, 0.9050, 1.82, 0.293, 324, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D (PDE4D) WITH PAPAVERINE.
318, p4ogbC_, 0.9049, 1.70, 0.299, 337, 311, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
319, d1y2jA_, 0.9049, 1.64, 0.297, 322, 310, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
320, d3sl8B_, 0.9048, 1.77, 0.301, 325, 312, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
321, d3ecnA_, 0.9048, 1.70, 0.299, 324, 311, CRYSTAL STRUCTURE OF PDE8A CATALYTIC DOMAIN IN COMPLEX WITH IBMX
322, d2qykB1, 0.9048, 1.73, 0.299, 324, 311, CRYSTAL STRUCTURE OF PDE4A10 IN COMPLEX WITH INHIBITOR NPV
323, d2qykA1, 0.9048, 1.77, 0.301, 325, 312, CRYSTAL STRUCTURE OF PDE4A10 IN COMPLEX WITH INHIBITOR NPV
324, p6f8xB_, 0.9047, 1.66, 0.297, 322, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 26G 
325, d1y2hA_, 0.9047, 1.67, 0.296, 324, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 1-(2- CHLORO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
326, d4kp6A_, 0.9046, 1.79, 0.322, 338, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B (PDE4B) IN COMPLEX WITH A [135]TRIAZINE DERIVATIVE
327, d3ly2A1, 0.9046, 1.79, 0.295, 333, 312, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
328, d3jwqB_, 0.9046, 1.80, 0.295, 333, 312, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
329, d2r8qB_, 0.9044, 1.80, 0.299, 324, 311, STRUCTURE OF LMJPDEB1 IN COMPLEX WITH IBMX
330, d3tgeA_, 0.9043, 1.66, 0.297, 322, 310, A NOVEL SERIES OF POTENT AND SELECTIVE PDE5 INHIBITOR1
331, d5b25A_, 0.9041, 1.73, 0.293, 324, 311, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
332, d1xlxA_, 0.9040, 1.90, 0.287, 334, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH CILOMILAST
333, p5lboC_, 0.9039, 1.82, 0.283, 324, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
334, d3tvxA1, 0.9039, 1.67, 0.277, 335, 311, THE STRUCTURE OF PDE4A WITH PENTOXIFYLLINE AT 2.84A RESOLUTION
335, d3ly2H_, 0.9039, 1.83, 0.293, 324, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
336, d3ly2G_, 0.9039, 1.97, 0.277, 335, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
337, d3ly2C_, 0.9039, 1.97, 0.277, 335, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
338, d1xotA_, 0.9039, 1.68, 0.297, 322, 310, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH VARDENAFIL
339, p6fdcB_, 0.9038, 1.65, 0.297, 323, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 32A 
340, p6f8uA_, 0.9038, 1.80, 0.295, 333, 312, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 20B 
341, d2qylA_, 0.9038, 1.97, 0.286, 332, 315, CRYSTAL STRUCTURE OF PDE4B2B IN COMPLEX WITH INHIBITOR NPV
342, p6f8uB_, 0.9037, 1.97, 0.286, 332, 315, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 20B 
343, d3jwqD_, 0.9037, 1.91, 0.287, 332, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
344, d4c1iB_, 0.9036, 1.65, 0.297, 322, 310, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
345, d3tvxB1, 0.9036, 1.67, 0.300, 324, 310, THE STRUCTURE OF PDE4A WITH PENTOXIFYLLINE AT 2.84A RESOLUTION
346, d3i8vB1, 0.9036, 1.57, 0.301, 322, 309, CRYSTAL STRUCTURE OF HUMAN PDE4A WITH 4-(3-BUTOXY-4-METHOXYPHENYL) METHYL-2-IMIDAZOLIDONE
347, p3g4gB_, 0.9036, 1.98, 0.287, 335, 314, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
348, d1y2hB_, 0.9036, 1.84, 0.299, 325, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 1-(2- CHLORO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
349, p6f8xA_, 0.9035, 1.83, 0.283, 323, 311, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 26G 
350, p6f8vB_, 0.9035, 1.85, 0.268, 320, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18B 
351, p6f8rA_, 0.9035, 1.82, 0.295, 333, 312, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 54 
352, d4c1iC_, 0.9035, 1.82, 0.295, 332, 312, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
353, p6f8rB_, 0.9034, 1.64, 0.297, 336, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 54 
354, p6f6uB_, 0.9033, 1.66, 0.297, 322, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 7B 
355, p6f8tB_, 0.9032, 1.58, 0.301, 322, 309, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 4A 
356, d1y2jB_, 0.9032, 1.68, 0.297, 324, 310, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
357, d3sl3C_, 0.9029, 1.58, 0.301, 322, 309, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
358, d3iadC_, 0.9029, 1.83, 0.268, 319, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
359, p4wziB2, 0.9028, 1.68, 0.300, 324, 310, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B
360, d3i8vA1, 0.9026, 1.69, 0.300, 324, 310, CRYSTAL STRUCTURE OF HUMAN PDE4A WITH 4-(3-BUTOXY-4-METHOXYPHENYL) METHYL-2-IMIDAZOLIDONE
361, d1ro9B_, 0.9026, 1.69, 0.300, 324, 310, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH 8-BR-AMP
362, d4c1iD_, 0.9025, 1.67, 0.297, 322, 310, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
363, d1xlxB_, 0.9023, 1.74, 0.296, 324, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH CILOMILAST
364, p4x0fA2, 0.9021, 1.81, 0.301, 339, 312, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B IN COMPLEX WITH (R)-(-)-ROLIPRAM
365, d5ohjB_, 0.9018, 1.93, 0.280, 329, 314, HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRROLIDINYL INHIBITOR.
366, d1xmuB_, 0.9018, 1.83, 0.295, 332, 312, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH ROFLUMILAST
367, d3sl8C_, 0.9017, 2.09, 0.285, 337, 316, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
368, p4w1oA_, 0.9016, 1.76, 0.269, 319, 309, PDE4D COMPLEXED WITH INHIBITOR
369, d1xmyA_, 0.9016, 1.69, 0.297, 322, 310, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- ROLIPRAM
370, d5k6jA_, 0.9012, 1.88, 0.281, 333, 313, HUMAN PHOSPODIESTERASE 4B IN COMPLEX WITH PYRIDYLOXY-BENZOXABOROLE BASED INHIBITOR
371, d3ly2E_, 0.9011, 1.94, 0.287, 335, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
372, d3kktA_, 0.9011, 1.67, 0.294, 321, 309, CRYSTAL STRUCTURE OF HUMAN PDE4B WITH 5-[3-[(1S2S4R)- BICYCLO[2.2.1]HEPT-2-YLOXY]-4-METHOXYP HENYL]TETRAHYDRO-2(1H)- PYRIMIDINONE REVEALS ORDERING OF THE C-TERMINAL HELIX RESIDUES 502- 509.
373, d1xlzA_, 0.9011, 1.78, 0.299, 324, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH FILAMINAST
374, p4x0fB2, 0.9009, 1.61, 0.298, 322, 309, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B IN COMPLEX WITH (R)-(-)-ROLIPRAM
375, d1xm4A_, 0.9009, 1.67, 0.294, 321, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH PICLAMILAST
376, d3o0jA_, 0.9008, 1.74, 0.294, 323, 310, PDE4B IN COMPLEX WITH LIGAND AN2898
377, d4wcuD_, 0.9007, 1.91, 0.288, 329, 313, PDE4 COMPLEXED WITH INHIBITOR
378, d2r8qA_, 0.9007, 2.19, 0.282, 347, 316, STRUCTURE OF LMJPDEB1 IN COMPLEX WITH IBMX
379, d1xm4B_, 0.9005, 1.68, 0.294, 321, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH PICLAMILAST
380, d5b25B_, 0.8999, 1.88, 0.281, 326, 313, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
381, d1xosA_, 0.8999, 1.67, 0.298, 321, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH SILDENAFIL
382, d4wcuA_, 0.8997, 1.74, 0.294, 323, 310, PDE4 COMPLEXED WITH INHIBITOR
383, d1xmyB_, 0.8996, 1.63, 0.294, 330, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- ROLIPRAM
384, p4wziA2, 0.8995, 1.74, 0.277, 335, 311, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B
385, d3w5eB_, 0.8995, 1.74, 0.277, 335, 311, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 31E
386, d1xlzB_, 0.8995, 1.67, 0.294, 321, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH FILAMINAST
387, d5k32B1, 0.8994, 1.81, 0.280, 332, 311, PDE4D CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
388, p4ogbB_, 0.8994, 1.73, 0.294, 319, 309, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
389, d3wd9B_, 0.8994, 1.65, 0.298, 330, 309, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 10F
390, d1f0jB_, 0.8994, 1.68, 0.298, 321, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B
391, p6f8wA_, 0.8991, 1.81, 0.286, 324, 311, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18A 
392, d5k32A_, 0.8985, 1.98, 0.288, 345, 313, PDE4D CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
393, d1xm6A_, 0.8981, 1.71, 0.294, 321, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- MESOPRAM
394, d4y2bA_, 0.8980, 1.71, 0.298, 320, 309, CO-CRYSTAL STRUCTURE OF 3-ETHYL-2-(ISOPROPYLAMINO)-7-(PYRIDIN-3-YL) THIENO[32-D]PYRIMIDIN-4(3H)-ONE BOUND TO PDE7A
395, d3wd9A_, 0.8980, 1.59, 0.299, 321, 308, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 10F
396, d4wcuC_, 0.8979, 1.99, 0.288, 345, 313, PDE4 COMPLEXED WITH INHIBITOR
397, d1xn0A_, 0.8978, 2.14, 0.285, 337, 316, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (RS)- ROLIPRAM
398, d5b25D_, 0.8975, 1.65, 0.302, 322, 308, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
399, p4w1oD_, 0.8974, 1.72, 0.298, 322, 309, PDE4D COMPLEXED WITH INHIBITOR
400, d3wymA_, 0.8973, 1.69, 0.295, 335, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(1H-PYRAZOL-1-YL)PHENYL)-5-METHOXY-3-(1-PHENYL-1H- PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
401, d3g3nA_, 0.8972, 1.74, 0.306, 318, 310, PDE7A CATALYTIC DOMAIN IN COMPLEX WITH 3-(26- DIFLUOROPHENYL)-2-(METHYLTHIO)QUINAZOLIN-4(3H)-ONE
402, d5h2rA_, 0.8968, 2.00, 0.281, 345, 313, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 15B
403, d5h2qA_, 0.8968, 1.63, 0.299, 322, 308, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 13E
404, d4pm0A_, 0.8968, 1.69, 0.295, 320, 308, PDE7A CATALYTIC DOMAIN IN COMPLEX WITH 2-(CYCLOPENTYLAMINO)THIENO[32- D]PYRIMIDIN-4(3H)-ONE DERIVATIVE
405, d1xn0B_, 0.8968, 1.85, 0.280, 332, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (RS)- ROLIPRAM
406, d1xm6B_, 0.8968, 1.63, 0.302, 317, 308, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- MESOPRAM
407, d3w5eA_, 0.8965, 1.76, 0.264, 315, 307, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 31E
408, p5l9hB_, 0.8963, 1.74, 0.310, 318, 310, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-340
409, d3sl3B_, 0.8961, 1.74, 0.310, 318, 310, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
410, d5b4kB_, 0.8960, 1.71, 0.286, 329, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH N-(4-((5-METHYL-5H-PYRROLO[32-D]PYRIMIDIN-4-YL)OXY)PHENYL)-1H- BENZIMIDAZOL-2-AMINE
411, d4ys7A1, 0.8957, 1.71, 0.286, 329, 308, CO-CRYSTAL STRUCTURE OF 2-[2-(58-DIMETHYL[124]TRIAZOLO[15- A]PYRAZIN-2-YL)ETHYL]-3-METHYL-3H-IMIDAZO[45-F]QUINOLINE (COMPOUND 39) WITH PDE10A
412, d3wymB_, 0.8957, 1.76, 0.310, 318, 310, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(1H-PYRAZOL-1-YL)PHENYL)-5-METHOXY-3-(1-PHENYL-1H- PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
413, d5g2bA_, 0.8956, 1.69, 0.295, 320, 308, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-008
414, d3wykA_, 0.8956, 1.71, 0.295, 331, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 3- (1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)PYRIDAZIN- 4(1H)-ONE
415, d2ouuA1, 0.8956, 2.03, 0.281, 345, 313, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CGMP
416, d5k9rA_, 0.8955, 1.82, 0.268, 334, 310, PDE10A WITH IMIDAZOPYRAZINE INHIBITOR
417, d4bbxB_, 0.8955, 1.60, 0.296, 320, 307, DISCOVERY OF A POTENT SELECTIVE AND ORALLY ACTIVE PDE10A INHIBITOR FOR THE TREATMENT OF SCHIZOPHRENIA
418, d3wi2B1, 0.8955, 1.86, 0.263, 316, 308, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH INHIBITOR
419, d5b4lB_, 0.8954, 1.77, 0.264, 321, 307, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH 1-(CYCLOPROPYLMETHYL)-5-(2-(23-DIHYDRO-1H-IMIDAZO[12- A]BENZIMIDAZOL-1-YL)ETHOXY)-3-(1-PHENYL-1H-PYRAZOL-5-YL)PYRIDAZIN- 4(1H)-ONE
420, d4ajdD1, 0.8954, 1.77, 0.264, 315, 307, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
421, d5b25C_, 0.8953, 1.83, 0.271, 333, 310, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
422, d4aelB1, 0.8953, 1.79, 0.264, 315, 307, PDE10A IN COMPLEX WITH THE INHIBITOR AZ5
423, p5l8cB_, 0.8952, 1.91, 0.260, 326, 308, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-039
424, d5g57A_, 0.8952, 1.67, 0.265, 312, 306, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
425, d4fcbA1, 0.8952, 1.66, 0.265, 312, 306, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
426, p5g5vA_, 0.8951, 1.89, 0.263, 322, 308, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-038
427, d2weyA1, 0.8949, 1.88, 0.263, 316, 308, HUMAN PDE-PAPAVERINE COMPLEX OBTAINED BY LIGAND SOAKING OF CROSS-LINKED PROTEIN CRYSTALS
428, d1zklA_, 0.8949, 1.79, 0.264, 321, 307, MULTIPLE DETERMINANTS FOR INHIBITOR SELECTIVITY OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
429, p5l8cA_, 0.8948, 1.89, 0.280, 332, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-039
430, d4llkA1, 0.8948, 1.80, 0.264, 321, 307, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT217
431, d4lljA1, 0.8948, 1.78, 0.269, 332, 309, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT214
432, d2ounA1, 0.8948, 1.84, 0.268, 333, 310, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH AMP
433, d4mrwA1, 0.8947, 1.78, 0.264, 321, 307, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0120 (7-CHLOROQUINOLIN-4- OL)
434, d2oupA1, 0.8947, 1.78, 0.272, 335, 309, CRYSTAL STRUCTURE OF PDE10A
435, d5b4lA_, 0.8946, 1.88, 0.263, 322, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH 1-(CYCLOPROPYLMETHYL)-5-(2-(23-DIHYDRO-1H-IMIDAZO[12- A]BENZIMIDAZOL-1-YL)ETHOXY)-3-(1-PHENYL-1H-PYRAZOL-5-YL)PYRIDAZIN- 4(1H)-ONE
436, d4msaA1, 0.8946, 1.73, 0.307, 317, 309, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0449 (5-NITRO-1H- BENZIMIDAZOLE)
437, d4mrzA1, 0.8946, 1.84, 0.271, 333, 310, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0429 (4-METHYL-3- NITROPYRIDIN-2-AMINE)
438, d4lm3A1, 0.8946, 1.91, 0.263, 327, 308, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT464
439, d4lm2A1, 0.8946, 1.91, 0.263, 327, 308, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT462
440, d4lm1A1, 0.8946, 1.90, 0.263, 322, 308, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT450
441, d4llxA1, 0.8946, 1.91, 0.263, 327, 308, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT434
442, d3wylB_, 0.8946, 1.90, 0.263, 322, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 5- METHOXY-3-(1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL) PYRIDAZIN-4(1H)-ONE
443, d4zo5B1, 0.8945, 1.82, 0.264, 315, 307, PDE10 COMPLEXED WITH 4-ISOPROPOXY-2-(2-(3-(4-METHOXYPHENYL)-4-OXO-34- DIHYDROQUINAZOLIN-2-YL)ETHYL)ISOINDOLINE-13-DIONE
444, d4ms0A1, 0.8945, 1.91, 0.263, 327, 308, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0443 (6-CHLOROPYRIMIDINE- 24-DIAMINE)
445, d4lkqA1, 0.8945, 1.91, 0.263, 327, 308, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT017
446, d3ui7A_, 0.8945, 1.92, 0.263, 328, 308, DISCOVERY OF ORALLY ACTIVE PYRAZOLOQUINOLINE AS A POTENT PDE10 INHIBITOR FOR THE MANAGEMENT OF SCHIZOPHRENIA
447, d4lm4A1, 0.8944, 1.92, 0.263, 327, 308, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT902
448, d3sniA1, 0.8944, 1.92, 0.263, 329, 308, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
449, d4yqhB_, 0.8943, 1.92, 0.263, 329, 308, 2-[2-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL]QUINOXALINE (SUNOVION COMPOUND 14) CO-CRYSTALLIZED WITH PDE10A
450, d4phlB_, 0.8943, 1.92, 0.263, 327, 308, TBRPDEB1-INHIBITOR COMPLEX
451, d2ouvA1, 0.8943, 1.80, 0.264, 313, 307, CRYSTAL STRUCTURE OF PDE10A2 MUTANT OF D564N
452, d5b4kA_, 0.8942, 1.80, 0.264, 321, 307, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH N-(4-((5-METHYL-5H-PYRROLO[32-D]PYRIMIDIN-4-YL)OXY)PHENYL)-1H- BENZIMIDAZOL-2-AMINE
453, d4ys7B_, 0.8942, 1.91, 0.263, 327, 308, CO-CRYSTAL STRUCTURE OF 2-[2-(58-DIMETHYL[124]TRIAZOLO[15- A]PYRAZIN-2-YL)ETHYL]-3-METHYL-3H-IMIDAZO[45-F]QUINOLINE (COMPOUND 39) WITH PDE10A
454, d4yqhA_, 0.8942, 1.92, 0.263, 327, 308, 2-[2-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL]QUINOXALINE (SUNOVION COMPOUND 14) CO-CRYSTALLIZED WITH PDE10A
455, d3ui7B_, 0.8942, 1.89, 0.263, 315, 308, DISCOVERY OF ORALLY ACTIVE PYRAZOLOQUINOLINE AS A POTENT PDE10 INHIBITOR FOR THE MANAGEMENT OF SCHIZOPHRENIA
456, d2y0jA_, 0.8942, 1.91, 0.263, 327, 308, TRIAZOLOQUINAZOLINES AS A NOVEL CLASS OF PHOSPHODIESTERASE 10A (PDE10A) INHIBITORS PART 2 LEAD-OPTIMISATION.
457, d2ousA1, 0.8942, 1.80, 0.264, 321, 307, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A
458, d1sojC_, 0.8942, 1.67, 0.265, 321, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
459, p5l8yB_, 0.8941, 1.86, 0.268, 332, 310, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-937
460, d5axpB_, 0.8941, 1.91, 0.260, 323, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(2-OXO-13-OXAZOLIDIN-3-YL)PHENYL)-5-METHOXY-3-(1-PHENYL- 1H-PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
461, d4lm0A1, 0.8941, 1.82, 0.264, 315, 307, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT448
462, d4ajgD1, 0.8941, 1.82, 0.264, 317, 307, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
463, d2ouqA1, 0.8941, 1.81, 0.264, 321, 307, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH GMP
464, d1sojI_, 0.8941, 1.82, 0.264, 315, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
465, d1sojE_, 0.8941, 1.81, 0.264, 314, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
466, d1sojA_, 0.8941, 1.91, 0.260, 323, 308, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
467, p5xujB_, 0.8940, 2.04, 0.267, 364, 311, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 7-(4-CHLOROPHENYL)-2- METHYLPYRAZOLO[15-A]PYRIMIDINE
468, p5g5vB_, 0.8940, 1.80, 0.269, 332, 309, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-038
469, d4mshA1, 0.8940, 1.80, 0.264, 315, 307, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0143 ((2S)-4-CHLORO-23- DIHYDRO-13-BENZOTHIAZOL-2-AMINE)
470, d4bbxA_, 0.8940, 1.92, 0.263, 327, 308, DISCOVERY OF A POTENT SELECTIVE AND ORALLY ACTIVE PDE10A INHIBITOR FOR THE TREATMENT OF SCHIZOPHRENIA
471, d2ouyA1, 0.8940, 1.69, 0.265, 321, 306, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D564A IN COMPLEX WITH CAMP.
472, d1sojK_, 0.8940, 1.92, 0.263, 324, 308, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
473, p5dh5A_, 0.8939, 2.04, 0.267, 364, 311, PDE10 COMPLEXED WITH N-[(1-METHYLPYRAZOL-4-YL)METHYL]-5-[[(1S2S)-2- (2-PYRIDYL)CYCLOPROPYL]METHOXY]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
474, d3wylA_, 0.8939, 2.04, 0.267, 364, 311, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 5- METHOXY-3-(1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL) PYRIDAZIN-4(1H)-ONE
475, d3sn7A1, 0.8939, 2.04, 0.267, 364, 311, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
476, d1sojG_, 0.8939, 1.81, 0.264, 322, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
477, d5uoyA_, 0.8938, 1.86, 0.268, 332, 310, CRYSTAL STRUCTURE OF HUMAN PDE1B CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 16J (6-(4-METHOXYBENZYL)-9-((TETRAHYDRO-2H-PYRAN-4-YL) METHYL)-891011-TETRAHYDROPYRIDO[4 3 :45]THIENO[32-E][12 4]TRIAZOLO[15-C]PYRIMIDIN-5(6H)-ONE)
478, d5c2eA1, 0.8938, 1.90, 0.263, 326, 308, PDE10 COMPLEXED WITH6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[2-(2-PYRIDYL)ETHOXY]PYRIMIDIN-4-AMINE
479, d3wykB_, 0.8938, 1.68, 0.265, 312, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 3- (1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)PYRIDAZIN- 4(1H)-ONE
480, d5dh4B1, 0.8937, 1.91, 0.260, 328, 308, PDE10 COMPLEXED WITH 5-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL) METHYL]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
481, d3ws9B1, 0.8937, 2.04, 0.267, 364, 311, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMDAZOLE INHIBITOR
482, d3ws8B1, 0.8937, 1.91, 0.263, 321, 308, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
483, d1sojL_, 0.8937, 1.83, 0.264, 315, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
484, d1sojH_, 0.8937, 1.81, 0.264, 321, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
485, d1sojF_, 0.8937, 2.05, 0.267, 364, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
486, d1sojD_, 0.8937, 1.73, 0.286, 321, 308, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
487, d1sojB_, 0.8937, 1.82, 0.264, 321, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
488, d5axpA_, 0.8936, 1.80, 0.264, 315, 307, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(2-OXO-13-OXAZOLIDIN-3-YL)PHENYL)-5-METHOXY-3-(1-PHENYL- 1H-PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
489, d1sojJ_, 0.8936, 1.69, 0.265, 321, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
490, d5axqB_, 0.8935, 1.91, 0.263, 322, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH HIGHLY POTENT AND BRAIN-PENETRANT PDE10A INHIBITOR WITH 2-OXINDOLE SCAFFOLD
491, d5axqA_, 0.8935, 1.92, 0.263, 322, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH HIGHLY POTENT AND BRAIN-PENETRANT PDE10A INHIBITOR WITH 2-OXINDOLE SCAFFOLD
492, d4zo5A1, 0.8935, 2.04, 0.267, 381, 311, PDE10 COMPLEXED WITH 4-ISOPROPOXY-2-(2-(3-(4-METHOXYPHENYL)-4-OXO-34- DIHYDROQUINAZOLIN-2-YL)ETHYL)ISOINDOLINE-13-DIONE
493, d4llpA1, 0.8935, 2.04, 0.267, 381, 311, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT401
494, d4ajdA1, 0.8935, 2.04, 0.267, 381, 311, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
495, d5k9rB_, 0.8934, 2.04, 0.267, 381, 311, PDE10A WITH IMIDAZOPYRAZINE INHIBITOR
496, d5h2rB_, 0.8934, 2.04, 0.267, 381, 311, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 15B
497, d5c1wA1, 0.8934, 2.04, 0.267, 381, 311, PDE10 COMPLEXED WITH 46-DICHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDINE
498, d4phlA_, 0.8934, 1.83, 0.264, 315, 307, TBRPDEB1-INHIBITOR COMPLEX
499, d3uuoB_, 0.8934, 2.04, 0.267, 381, 311, THE DISCOVERY OF POTENT SELECTIVITY AND ORALLY BIOAVAILABLE PYROZOLOQUINOLINES AS PDE10 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
500, d3snlA1, 0.8934, 1.92, 0.263, 316, 308, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
501, p5l9hA_, 0.8933, 1.84, 0.264, 315, 307, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-340
502, d4fcdA1, 0.8933, 1.81, 0.264, 321, 307, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
503, d5xkmE_, 0.8932, 1.93, 0.263, 327, 308, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
504, d5c28A1, 0.8932, 1.92, 0.263, 322, 308, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDIN-4-AMINE
505, d5h2qB_, 0.8931, 1.71, 0.265, 312, 306, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 13E
506, p5xuiA_, 0.8930, 1.71, 0.290, 328, 307, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 2-METHYL-5-[2-([12 4]TRIAZOLO[15-A]PYRIMIDIN-2-YL)ET HYL]PYRAZOLO[15-A]PYRIMIDIN-7-OL
507, d2ourA1, 0.8930, 1.92, 0.263, 323, 308, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CAMP
508, d5dh5B1, 0.8929, 1.76, 0.273, 330, 308, PDE10 COMPLEXED WITH N-[(1-METHYLPYRAZOL-4-YL)METHYL]-5-[[(1S2S)-2- (2-PYRIDYL)CYCLOPROPYL]METHOXY]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
509, d4mscA1, 0.8929, 1.83, 0.264, 315, 307, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1595 (2-[(QUINOLIN-7- YLOXY)METHYL]QUINOLINE)
510, d1so2B_, 0.8929, 1.80, 0.264, 321, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
511, d5c2hB1, 0.8928, 1.88, 0.268, 333, 310, PDE10 COMPLEXED WITH 6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[3-(2-QUINOLYL)PROPOXY]PYRIMIDIN-4-AMINE
512, d5c2aA1, 0.8928, 1.82, 0.264, 321, 307, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-N-[(24-DIMETHYLTHIAZOL-5- YL)METHYL]-5-METHYL-PYRIMIDIN-4-AMINE
513, d4wn1A1, 0.8928, 2.12, 0.256, 319, 312, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 1-METHYL-5-(1-METHYL-3- {[4-(QUINOLIN-2-YL)PHENOXY]METHYL}-1H-PYRAZOL-4-YL)PYRIDIN-2(1H)-ONE
514, d5g2bB_, 0.8927, 2.01, 0.262, 323, 309, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-008
515, d4i15A_, 0.8927, 1.71, 0.290, 328, 307, CRYSTAL STRUCTURE OF TBRPDEB1
516, d2y0jB_, 0.8927, 1.69, 0.265, 322, 306, TRIAZOLOQUINAZOLINES AS A NOVEL CLASS OF PHOSPHODIESTERASE 10A (PDE10A) INHIBITORS PART 2 LEAD-OPTIMISATION.
517, d4ajmD_, 0.8926, 1.80, 0.261, 322, 307, DEVELOPMENT OF A PLATE-BASED OPTICAL BIOSENSOR METHODOLOGY TO IDENTIFY PDE10 FRAGMENT INHIBITORS
518, d3ws9A1, 0.8926, 1.85, 0.264, 321, 307, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMDAZOLE INHIBITOR
519, d1so2D_, 0.8925, 1.90, 0.263, 327, 308, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
520, p5l8yA_, 0.8924, 2.14, 0.264, 363, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-937
521, d4p1rB_, 0.8924, 1.61, 0.266, 320, 305, CRYSTAL STRUCTURE OF PDE10A WITH IMIDAZO[45-B]PYRIDINES AS POTENT AND SELECTIVE INHIBITORS
522, d4i15B_, 0.8924, 1.84, 0.264, 321, 307, CRYSTAL STRUCTURE OF TBRPDEB1
523, d3lxgA_, 0.8924, 1.94, 0.263, 322, 308, CRYSTAL STRUCTURE OF RAT PHOSPHODIESTERASE 10A IN COMPLEX WITH LIGAND WEB-3
524, d5c2hA_, 0.8923, 1.82, 0.272, 332, 309, PDE10 COMPLEXED WITH 6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[3-(2-QUINOLYL)PROPOXY]PYRIMIDIN-4-AMINE
525, d4msnA1, 0.8923, 1.88, 0.268, 333, 310, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0451 (8-NITROQUINOLINE)
526, d4heuB_, 0.8923, 1.84, 0.264, 314, 307, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR ((1-(3-(4- ((1H-BENZO[D]IMIDAZOL-2-YL)AMINO)PHENOXY)PYRIDIN-2-YL)PIPERIDIN-4- YL)METHANOL)
527, d1so2C_, 0.8923, 1.76, 0.265, 320, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
528, d1so2A_, 0.8923, 1.84, 0.264, 322, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
529, p5xuiB_, 0.8922, 2.07, 0.267, 365, 311, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 2-METHYL-5-[2-([12 4]TRIAZOLO[15-A]PYRIMIDIN-2-YL)ET HYL]PYRAZOLO[15-A]PYRIMIDIN-7-OL
530, d4wn1B1, 0.8922, 1.89, 0.271, 333, 310, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 1-METHYL-5-(1-METHYL-3- {[4-(QUINOLIN-2-YL)PHENOXY]METHYL}-1H-PYRAZOL-4-YL)PYRIDIN-2(1H)-ONE
531, d4ajfA1, 0.8922, 1.58, 0.262, 308, 305, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
532, d5g57B_, 0.8920, 2.00, 0.267, 333, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
533, d4ajgA1, 0.8920, 1.65, 0.262, 308, 305, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
534, d5c2eB1, 0.8919, 1.60, 0.266, 308, 305, PDE10 COMPLEXED WITH6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[2-(2-PYRIDYL)ETHOXY]PYRIMIDIN-4-AMINE
535, d5c2aB1, 0.8918, 1.80, 0.264, 327, 307, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-N-[(24-DIMETHYLTHIAZOL-5- YL)METHYL]-5-METHYL-PYRIMIDIN-4-AMINE
536, d5uwfC1, 0.8916, 1.57, 0.262, 308, 305, CRYSTAL STRUCTURE OF HUMAN PDE10A IN COMPLEX WITH INHIBITOR 16D
537, p5w6eA_, 0.8914, 1.90, 0.269, 372, 309, PDE1B COMPLEXED WITH COMPOUND 3S 
538, d5up0A_, 0.8914, 2.09, 0.267, 363, 311, CRYSTAL STRUCTURE OF HUMAN PDE1B CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 3 (6-(4-CHLOROBENZYL)-891011-TETRAHYDROBENZO[4 5]THIENO[32-E][124]TRIAZOLO[15-C]PYRIMIDIN-5(6H)-ONE)
539, d4npwA_, 0.8914, 1.84, 0.264, 322, 307, CRYSTAL STRUCTURE OF HUMAN PDE1B BOUND TO INHIBITOR 19A (78- DIMETHOXY-N-[(2S)-1-(3-METHYL-1H-PYRAZOL-5-YL)PROPAN-2-YL]QUINAZOLIN- 4-AMINE)
540, d4mvhB_, 0.8914, 1.92, 0.263, 322, 308, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
541, d3ws8A1, 0.8913, 1.90, 0.264, 325, 307, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
542, d4p0nB_, 0.8910, 1.84, 0.269, 332, 309, CRYSTAL STRUCTURE OF PDE10A WITH A NOVEL IMIDAZO[45-B]PYRIDINE INHIBITOR
543, d4hf4B_, 0.8910, 1.76, 0.265, 320, 306, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR (1-(1-(3-(4- (BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRAZIN-2-YL)PIPERIDIN-4-YL) ETHANOL)
544, d5uwfD1, 0.8909, 1.72, 0.265, 321, 306, CRYSTAL STRUCTURE OF HUMAN PDE10A IN COMPLEX WITH INHIBITOR 16D
545, d4mseA1, 0.8907, 1.72, 0.265, 321, 306, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1597 (2-({[(2S)-2-METHYL- 23-DIHYDRO-13-BENZOTHIAZOL-5-YL]OXY}METHYL)QUINOLINE)
546, d4ddlB_, 0.8907, 1.78, 0.265, 320, 306, PDE10A CRYSTAL STRUCTURE COMPLEXED WITH NOVEL INHIBITOR
547, d4aelA1, 0.8907, 1.80, 0.285, 321, 309, PDE10A IN COMPLEX WITH THE INHIBITOR AZ5
548, d3wi2A1, 0.8906, 1.77, 0.286, 321, 308, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH INHIBITOR
549, d2weyB1, 0.8906, 1.80, 0.285, 321, 309, HUMAN PDE-PAPAVERINE COMPLEX OBTAINED BY LIGAND SOAKING OF CROSS-LINKED PROTEIN CRYSTALS
550, d5dh4A_, 0.8905, 1.59, 0.262, 308, 305, PDE10 COMPLEXED WITH 5-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL) METHYL]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
551, d4npvA_, 0.8899, 1.72, 0.265, 322, 306, CRYSTAL STRUCTURE OF HUMAN PDE1B BOUND TO INHIBITOR 7A (678- TRIMETHOXY-N-(PENTAN-3-YL)QUINAZOLIN-4-AMINE)
552, d4heuA_, 0.8898, 1.60, 0.262, 308, 305, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR ((1-(3-(4- ((1H-BENZO[D]IMIDAZOL-2-YL)AMINO)PHENOXY)PYRIDIN-2-YL)PIPERIDIN-4- YL)METHANOL)
553, d4p1rA_, 0.8897, 1.61, 0.262, 308, 305, CRYSTAL STRUCTURE OF PDE10A WITH IMIDAZO[45-B]PYRIDINES AS POTENT AND SELECTIVE INHIBITORS
554, d4xy2B1, 0.8896, 1.73, 0.265, 321, 306, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH ASP9436
555, d4dffA_, 0.8895, 1.95, 0.263, 327, 308, THE SAR DEVELOPMENT OF DIHYDROIMIDAZOISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
556, d4tppB_, 0.8894, 1.60, 0.262, 308, 305, 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS NOVEL PDE10A INHIBITORS
557, d4muwA_, 0.8894, 1.73, 0.266, 319, 305, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
558, d2o8hA_, 0.8894, 1.74, 0.265, 322, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF RAT PHOSPHODIESTERASE 10A
559, d4tpmB_, 0.8892, 2.01, 0.263, 322, 308, CRYSTAL STRUCTURE OF 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS PDE10A INHIBITORS
560, d4hf4A_, 0.8889, 1.59, 0.266, 307, 304, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR (1-(1-(3-(4- (BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRAZIN-2-YL)PIPERIDIN-4-YL) ETHANOL)
561, d5ediC_, 0.8887, 1.75, 0.282, 323, 308, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
562, d5ediB1, 0.8887, 1.71, 0.262, 318, 305, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
563, d5edhB1, 0.8887, 1.72, 0.262, 318, 305, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
564, d4ajmA1, 0.8885, 1.90, 0.265, 320, 306, DEVELOPMENT OF A PLATE-BASED OPTICAL BIOSENSOR METHODOLOGY TO IDENTIFY PDE10 FRAGMENT INHIBITORS
565, d5edgC_, 0.8884, 1.59, 0.266, 307, 304, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
566, d4ddlA_, 0.8884, 1.57, 0.263, 307, 304, PDE10A CRYSTAL STRUCTURE COMPLEXED WITH NOVEL INHIBITOR
567, d5edhC_, 0.8882, 1.72, 0.262, 318, 305, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
568, d4mvhA_, 0.8882, 1.68, 0.263, 307, 304, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
569, d3qpoA_, 0.8882, 1.59, 0.263, 307, 304, STRUCTURE OF PDE10-INHIBITOR COMPLEX
570, d5i2rB_, 0.8881, 1.73, 0.262, 318, 305, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
571, d5edeC_, 0.8881, 1.77, 0.262, 312, 305, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
572, d5edgB1, 0.8880, 1.80, 0.266, 318, 305, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
573, d5c29A_, 0.8880, 1.79, 0.262, 312, 305, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-N-PROPYL- PYRIMIDIN-4-AMINE
574, d3qpnA_, 0.8879, 1.72, 0.263, 318, 304, STRUCTURE OF PDE10-INHIBITOR COMPLEX
575, d5ediA_, 0.8878, 1.77, 0.262, 312, 305, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
576, d5edgA_, 0.8875, 1.73, 0.262, 318, 305, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
577, d4p0nA_, 0.8875, 1.80, 0.262, 312, 305, CRYSTAL STRUCTURE OF PDE10A WITH A NOVEL IMIDAZO[45-B]PYRIDINE INHIBITOR
578, d3hr1A_, 0.8875, 1.63, 0.263, 307, 304, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
579, d3hqzA_, 0.8875, 1.43, 0.265, 305, 302, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
580, d5edeB1, 0.8872, 2.03, 0.261, 316, 307, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
581, d5u7dB_, 0.8871, 1.77, 0.262, 312, 305, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
582, d2ovyA_, 0.8871, 1.81, 0.262, 313, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF RAT PHOSPHODIESTERASE 10A
583, d5edhA_, 0.8870, 1.67, 0.266, 307, 304, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
584, d3hqyA_, 0.8869, 1.43, 0.265, 305, 302, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
585, d5i2rC_, 0.8868, 1.80, 0.262, 312, 305, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
586, d4muwB_, 0.8868, 1.79, 0.262, 312, 305, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
587, d3qppA_, 0.8868, 1.64, 0.263, 307, 304, STRUCTURE OF PDE10-INHIBITOR COMPLEX
588, d4phwB_, 0.8867, 1.44, 0.265, 305, 302, CRYSTAL STRUCTURE OF PDE10A WITH 1H-BENZIMIDAZOL-2-YL(4-((3- (TETRAHYDRO-2H-PYRAN-4-YL)-2-PYRIDINYL)OXY)PHENYL)METHANONE
589, d5edeA_, 0.8865, 1.44, 0.265, 305, 302, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
590, d4phwA_, 0.8860, 1.82, 0.262, 312, 305, CRYSTAL STRUCTURE OF PDE10A WITH 1H-BENZIMIDAZOL-2-YL(4-((3- (TETRAHYDRO-2H-PYRAN-4-YL)-2-PYRIDINYL)OXY)PHENYL)METHANONE
591, d4tppA_, 0.8851, 2.19, 0.254, 328, 311, 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS NOVEL PDE10A INHIBITORS
592, d3uuoA_, 0.8851, 1.45, 0.265, 305, 302, THE DISCOVERY OF POTENT SELECTIVITY AND ORALLY BIOAVAILABLE PYROZOLOQUINOLINES AS PDE10 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
593, d5i2rA_, 0.8850, 1.82, 0.262, 311, 305, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
594, d5xkmF_, 0.8849, 1.46, 0.265, 305, 302, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
595, d5ediD_, 0.8849, 1.80, 0.262, 312, 305, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
596, d5edgD1, 0.8848, 1.56, 0.264, 306, 303, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
597, d5edhD1, 0.8847, 1.45, 0.265, 305, 302, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
598, d2ovvA_, 0.8843, 1.46, 0.265, 305, 302, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF RAT PHOSPHODIESTERASE 10A
599, d5edeD1, 0.8842, 1.81, 0.262, 313, 305, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
600, d3v93C_, 0.8839, 1.47, 0.265, 305, 302, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
601, d3kktB_, 0.8837, 1.51, 0.265, 305, 302, CRYSTAL STRUCTURE OF HUMAN PDE4B WITH 5-[3-[(1S2S4R)- BICYCLO[2.2.1]HEPT-2-YLOXY]-4-METHOXYP HENYL]TETRAHYDRO-2(1H)- PYRIMIDINONE REVEALS ORDERING OF THE C-TERMINAL HELIX RESIDUES 502- 509.
602, d5i2rD1, 0.8831, 1.55, 0.265, 305, 302, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
603, d3v93G_, 0.8821, 1.84, 0.262, 312, 305, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
604, d3hqwA_, 0.8819, 2.23, 0.261, 321, 310, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
605, d3v93F_, 0.8811, 1.63, 0.264, 316, 303, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
606, d3v94C_, 0.8810, 1.63, 0.264, 311, 303, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
607, d4tpmA_, 0.8806, 1.63, 0.264, 310, 303, CRYSTAL STRUCTURE OF 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS PDE10A INHIBITORS
608, d3v93B_, 0.8805, 1.45, 0.266, 304, 301, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
609, d3v94D_, 0.8795, 1.64, 0.264, 311, 303, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
610, d3v94E_, 0.8792, 2.08, 0.263, 333, 308, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
611, d3v94G_, 0.8773, 2.01, 0.292, 338, 308, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
612, d3v94H_, 0.8772, 1.66, 0.264, 311, 303, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
613, d5vp0C_, 0.8764, 2.18, 0.262, 334, 309, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
614, d3v94A_, 0.8764, 1.44, 0.263, 303, 300, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
615, d3v93E_, 0.8763, 2.20, 0.262, 334, 309, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
616, d3v93H_, 0.8762, 2.20, 0.262, 334, 309, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
617, d3v94F_, 0.8761, 1.99, 0.265, 333, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
618, d3v94B_, 0.8754, 1.46, 0.263, 303, 300, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
619, d1tazA_, 0.8735, 2.11, 0.260, 333, 308, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 1B
620, d3v93A_, 0.8732, 2.00, 0.265, 331, 306, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
621, d4ajfD1, 0.8717, 1.98, 0.268, 331, 306, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
622, d4lm3B1, 0.8716, 2.04, 0.265, 334, 306, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT464
623, d4mscB1, 0.8715, 2.00, 0.266, 330, 305, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1595 (2-[(QUINOLIN-7- YLOXY)METHYL]QUINOLINE)
624, d4lm2B1, 0.8715, 2.06, 0.262, 311, 305, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT462
625, d4llxB1, 0.8715, 2.06, 0.265, 332, 306, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT434
626, d4mrzB1, 0.8714, 1.91, 0.270, 329, 304, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0429 (4-METHYL-3- NITROPYRIDIN-2-AMINE)
627, d4llkB1, 0.8714, 1.90, 0.264, 328, 303, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT217
628, d4msnB1, 0.8712, 2.06, 0.261, 334, 306, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0451 (8-NITROQUINOLINE)
629, d2ouvB1, 0.8712, 2.08, 0.261, 334, 306, CRYSTAL STRUCTURE OF PDE10A2 MUTANT OF D564N
630, d4lkqB1, 0.8710, 1.80, 0.282, 321, 301, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT017
631, d4ms0B_, 0.8709, 1.95, 0.266, 329, 304, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0443 (6-CHLOROPYRIMIDINE- 24-DIAMINE)
632, d4msaB1, 0.8708, 2.33, 0.264, 322, 307, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0449 (5-NITRO-1H- BENZIMIDAZOLE)
633, d4mrwB1, 0.8708, 2.58, 0.258, 326, 310, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0120 (7-CHLOROQUINOLIN-4- OL)
634, d4lm4B1, 0.8708, 2.57, 0.261, 326, 310, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT902
635, d4mseB1, 0.8707, 2.58, 0.258, 326, 310, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1597 (2-({[(2S)-2-METHYL- 23-DIHYDRO-13-BENZOTHIAZOL-5-YL]OXY}METHYL)QUINOLINE)
636, d4lm1B1, 0.8707, 2.58, 0.258, 326, 310, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT450
637, d4lm0B1, 0.8706, 2.59, 0.258, 326, 310, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT448
638, d4mshB1, 0.8704, 2.60, 0.258, 326, 310, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0143 ((2S)-4-CHLORO-23- DIHYDRO-13-BENZOTHIAZOL-2-AMINE)
639, d2ousB1, 0.8704, 2.43, 0.260, 324, 308, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A
640, d2ounB1, 0.8696, 2.58, 0.255, 325, 310, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH AMP
641, d2oupB1, 0.8688, 2.60, 0.258, 326, 310, CRYSTAL STRUCTURE OF PDE10A
642, d5u7lB_, 0.8680, 2.61, 0.261, 324, 310, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
643, d1udtA_, 0.8673, 2.60, 0.261, 326, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH SILDENAFIL(VIAGRA)
644, p3jbqB_, 0.8665, 2.51, 0.259, 323, 309, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
645, d1uhoA_, 0.8665, 2.61, 0.258, 326, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH VARDENAFIL(LEVITRA)
646, p3jbqF_, 0.8655, 2.59, 0.258, 326, 310, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
647, d2h42A_, 0.8653, 2.52, 0.259, 323, 309, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH SILDENAFIL
648, d3v93D_, 0.8650, 2.62, 0.258, 326, 310, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
649, d4lljB1, 0.8634, 2.54, 0.259, 324, 309, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT214
650, d1uduB_, 0.8630, 2.60, 0.255, 326, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH TADALAFIL(CIALIS)
651, d1uduA_, 0.8629, 2.62, 0.261, 325, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH TADALAFIL(CIALIS)
652, d2h42C_, 0.8596, 2.39, 0.261, 322, 307, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH SILDENAFIL
653, d2h42B_, 0.8573, 2.12, 0.261, 310, 303, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH SILDENAFIL
654, d2h44A_, 0.8556, 2.10, 0.276, 313, 301, CRYSTAL STRUCTURE OF PDE5A1 IN COMPLEX WITH ICARISID II
655, d4xy2A1, 0.8500, 2.27, 0.289, 328, 311, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH ASP9436
656, d4fcbB1, 0.8484, 2.13, 0.276, 313, 301, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
657, d3snlB1, 0.8482, 2.28, 0.289, 328, 311, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
658, d4fcdB1, 0.8471, 2.08, 0.279, 326, 301, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
659, d3sn7B1, 0.8467, 1.83, 0.268, 324, 299, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
660, d3sniB1, 0.8458, 2.50, 0.261, 321, 306, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
661, p5xujA_, 0.8440, 2.17, 0.276, 313, 301, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 7-(4-CHLOROPHENYL)-2- METHYLPYRAZOLO[15-A]PYRIMIDINE
662, d1rkpA_, 0.8423, 2.17, 0.276, 313, 301, CRYSTAL STRUCTURE OF PDE5A1-IBMX
663, d3bjcA_, 0.8399, 2.00, 0.274, 317, 299, CRYSTAL STRUCTURE OF THE PDE5A CATALYTIC DOMAIN IN COMPLEX WITH A NOVEL INHIBITOR
664, d2h40A_, 0.8359, 2.25, 0.276, 317, 301, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF UNLIGANDED PDE5
665, d5c1wB1, 0.8358, 2.10, 0.272, 326, 298, PDE10 COMPLEXED WITH 46-DICHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDINE
666, d3sieB_, 0.8344, 1.99, 0.264, 310, 295, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
667, d3shyA_, 0.8290, 1.81, 0.266, 308, 293, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
668, d2ouuB1, 0.8273, 1.82, 0.266, 308, 293, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CGMP
669, d3sieA_, 0.8267, 1.84, 0.266, 308, 293, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
670, d3shzA_, 0.8267, 1.85, 0.266, 308, 293, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
671, d4md6A_, 0.8230, 1.86, 0.266, 308, 293, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH INHIBITOR 5R
672, p3ibjB3, 0.8229, 1.85, 0.264, 308, 292, X-RAY STRUCTURE OF PDE2A
673, d4oexA1, 0.8210, 2.43, 0.263, 311, 297, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
674, d4i9zA_, 0.8209, 2.54, 0.275, 311, 298, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
675, d2ouqB1, 0.8192, 2.57, 0.267, 311, 296, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH GMP
676, d4g2yA1, 0.8166, 2.31, 0.261, 311, 295, CRYSTAL STRUCTURE OF PDE5A COMPLEXED WITH ITS INHIBITOR
677, d5c28B1, 0.8161, 1.91, 0.253, 300, 288, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDIN-4-AMINE
678, d2ouyB1, 0.8158, 1.98, 0.268, 298, 287, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D564A IN COMPLEX WITH CAMP.
679, p3ibjA3, 0.8135, 2.50, 0.258, 309, 295, X-RAY STRUCTURE OF PDE2A
680, d2ourB1, 0.8134, 2.01, 0.265, 297, 287, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CAMP
681, d5c29B_, 0.8111, 1.97, 0.262, 297, 286, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-N-PROPYL- PYRIMIDIN-4-AMINE
682, d4ia0A_, 0.8111, 2.18, 0.265, 299, 287, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
683, d4dffB_, 0.8086, 2.48, 0.254, 319, 291, THE SAR DEVELOPMENT OF DIHYDROIMIDAZOISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
684, d4oewA_, 0.8085, 1.98, 0.268, 296, 284, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
685, d3itmA_, 0.8058, 1.97, 0.261, 296, 284, CATALYTIC DOMAIN OF HPDE2A
686, d3b2rA2, 0.8022, 2.37, 0.262, 306, 290, CRYSTAL STRUCTURE OF PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH VARDENAFIL
687, d4g2wA_, 0.8020, 2.11, 0.261, 296, 284, CRYSTAL STRUCTURE OF PDE5A IN COMPLEX WITH ITS INHIBITOR
688, d4llpB1, 0.8003, 2.72, 0.256, 315, 293, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT401
689, d3itmB_, 0.8003, 2.43, 0.255, 306, 290, CATALYTIC DOMAIN OF HPDE2A
690, d3itmD_, 0.7997, 2.31, 0.248, 331, 286, CATALYTIC DOMAIN OF HPDE2A
691, d1t9rA_, 0.7965, 2.57, 0.254, 312, 291, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A
692, d3b2rB_, 0.7923, 2.19, 0.263, 288, 285, CRYSTAL STRUCTURE OF PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH VARDENAFIL
693, d3itmC_, 0.7894, 1.95, 0.264, 292, 280, CATALYTIC DOMAIN OF HPDE2A
694, d2qymA_, 0.7749, 1.52, 0.269, 277, 275, CRYSTAL STRUCTURE OF UNLIGANDED PDE4C2
695, p6b96A1, 0.6373, 1.95, 0.272, 289, 279, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPOUND 16
696, p6b96B1, 0.6359, 2.56, 0.255, 307, 286, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPOUND 16
697, p6b97A1, 0.6355, 2.18, 0.257, 293, 280, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPLEX 9
698, p6b98B1, 0.6349, 1.88, 0.272, 286, 276, PDE2 IN COMPLEX WITH COMPOUND 1
699, p5vydA1, 0.6248, 2.59, 0.252, 303, 286, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE DOMAIN OF RHOPDE FUSION PROTEIN FROM THE CHOANOFLAGELLATE SALPINGOECA ROSETTA
700, p5vydB1, 0.6191, 2.66, 0.256, 318, 285, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE DOMAIN OF RHOPDE FUSION PROTEIN FROM THE CHOANOFLAGELLATE SALPINGOECA ROSETTA
701, p5vp1C1, 0.5982, 2.57, 0.257, 318, 284, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
702, p6ezfA1, 0.5962, 2.61, 0.251, 301, 283, PDE2 IN COMPLEX WITH MOLECULE 5
